← Leaderboards
Luke Lee Lairson
University Of Tx Md Anderson Can Ctr
$5,079,594
Attributed
$7,060,202
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,060,202 · 5
By mechanism
R01$6,110,093 · 3
R21$532,125 · 1
R56$417,984 · 1
Top collaborators
- Sendurai Ayyavoo Mani5 shared
- Howard C Hang1 shared
- Christopher G Parker1 shared
- Andrew Barrett Ward1 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Khandan Keyomarsi$13,000,468
- Jian Hu$8,609,311
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoMalignant NeoplasmsProteinsPhenotypeSmall MoleculeSignal TransductionMass Spectrum AnalysisCellsPropertyCell TypeRecurrenceMolecular TargetDrug DevelopmentNeoplastic CellRodentResistanceDoseEffective TherapySurvival RateTumorCancer Stem CellTumor InitiationStem-Like CellBase
Grant awards (14)
Chemoproteomic discovery and functional analysis microbiota bile acid-protein targets in host immunity$891,678
R01 · FY2025 · AI
A chemical biology-based approach to the study of FOXP3 and Regulatory T Cell Fate$417,984
R56 · FY2025 · AI · contact PI
A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma$429,916
R01 · FY2023 · NS · contact PI
A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma$528,172
R01 · FY2022 · NS · contact PI
A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma$534,558
R01 · FY2021 · NS · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$483,655
R01 · FY2021 · CA
A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma$544,136
R01 · FY2020 · NS · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$535,276
R01 · FY2020 · CA
Pathogenesis and Novel Therapeutics to Reverse T Cell Exhaustion in Persistent Viral Infections$241,875
R21 · FY2020 · AI · contact PI
A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma$557,933
R01 · FY2019 · NS · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$519,217
R01 · FY2019 · CA
Pathogenesis and Novel Therapeutics to Reverse T Cell Exhaustion in Persistent Viral Infections$290,250
R21 · FY2019 · AI · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$535,276
R01 · FY2018 · CA
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$550,276
R01 · FY2017 · CA